TrialJCO precision oncology2022

Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.

Ibiayi Dagogo-Jack et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.